HDAC8 and acute myeloid leukemia: This is in agreement with findings of Qi et al. (2015) that showed that leukemic cells bearing inv(16) linked to high expression levels of HDAC8 (5–12 times that of CD34+ cells from healthy donors) were particularly responsive to treatment with PCI, although also non-inv(16) AML blasts showed a degree of sensitivity.